| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Wednesday, Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2023 revenues of $291 million, down from $357 million a year ago, missing the consensus of $321.97 million. Total revenue for 2023 was $984 million, compared to $2 billion in the same period in 2022.
Net loss for the fourth quarter of 2023 was $178 million, compared to a net loss of $182 million a year ago.
Novavax’s fourth quarter EPS loss reached $(1.44), up from $(2.28) a year ago compared to the consensus of $(0.45).
The company expects to initiate a pivotal Phase 3 trial for the COVID-19-Influenza Combination (CIC) vaccine candidate in the second half of 2024, with the potential for accelerated approval and anticipated launch in 2026.
Novavax says restructuring resulted in approximately a 30% reduction in the workforce compared to the first quarter of 2023.
In May 2023, the company announced a global restructuring and cost reduction plan. Additionally, in January 2024, it announced an additional 12% reduction of the global workforce, comprised of an additional 9% reduction in the company’s full-time employees and the remainder comprised contractors and consultants.
Last week, Novavax said it reached a settlement with Gavi regarding the 2021 advance purchase agreement for Novavax’s prototype COVID-19 vaccine. The agreement brings the pending arbitration related to the advance purchase agreement to a close.
Guidance: Novavax forecasts fiscal year 2024 revenue of $800 million-$1 billion versus the consensus of $969.56 million, with combined R&D and SG&A expenses of $700 million-$800 million.
Full-year 2024 guidance reflects Advance Purchase Agreement (APA) expected dose delivery schedules of $500 million to $600 million and non-APA related revenue of $300 million to $400 million from a combination of commercial market product sales.
Novavax expects Q1 fiscal year 2024 revenue of approximately $100 million versus consensus of $292.33 million.
Novavax says the total potential contract value for APAs outstanding as of December 31, 2023, was over $1 billion related to expected dose deliveries for 2024 through 2026.
Price Action: NVAX shares are down 29.30% at $4.25 on the last check Wednesday.
Photo: Marco Verch from Flickr.
Posted In: NVAX
